YOLFTbeta
60

Zhejiang Gongdong Medical Technology Co Ltd

605369 · SHG · Healthcare / Medical Instruments & Supplies

17.41CNY-0.35 (-1.97%)

Price History

Full chart

Market Stats

Previous Close17.76
Open17.70
Day Range17.31 – 17.83
52-Week Range14.75 – 22.46
Volume1.23M
Market Cap4.00B
P/E (TTM)72.80
Forward P/E0.00
EPS0.25
Dividend Yield0.82%
Beta0.59
50-Day Avg16.98
200-Day Avg18.04

About

Zhejiang Gongdong Medical Technology Co., Ltd. researches, develops, produces, and sells disposable medical consumables in China and internationally. Its products include blood collection tubes, needles, and needle holders, as well as sharp containers; cell culture dishes, plates, bottles, and flasks; serological pipette products; laboratory consumables, such as petri dishes, centrifuge and cryo tubes, pipette tips, transfer pipettes, cuvettes, and test tubes; and urine, stool, and sputum specimen collection containers. The company also offers vaginal, ear, and anus speculum products, as well as sponge forceps nursing plasticwares; and customized solutions, including bespoke plastic medical products. Zhejiang Gongdong Medical Technology Co., Ltd. was founded in 1985 and is based in Taizhou, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Weifeng Zhong
  • Employees1.66K
  • HeadquartersNo. 10, Beiyuan Avenue, Taizhou, China, 318020, China
  • Websitehttps://www.gongdong.com

Leadership

  • Mr. Weifeng ZhongGM & Director · b. 1977
  • Mr. Yong ZhuDeputy GM & CFO · b. 1979
  • Mr. Shangxiao LaiDeputy General Manager · b. 1978
  • Ms. Ling Ting MuSecretary · b. 1990

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue371.25M431.30M482.55M552.98M829.65M1.19B1.47B975.08M1.12B1.14B
Growth (%)-+16.18%+11.88%+14.59%+50.03%+43.95%+22.98%-33.61%+14.37%+1.84%
Cost of Revenue220.08M251.20M285.97M308.10M439.12M668.83M894.14M661.42M752.09M819.18M
Gross Profit151.17M180.10M196.58M244.88M390.53M525.42M574.54M313.66M363.12M316.52M
Gross Margin40.72%41.76%40.74%44.28%47.07%44.00%39.12%32.17%32.56%27.87%
Operating Expense80.55M112.96M100.01M112.47M127.27M165.70M202.71M193.94M171.54M203.32M
Operating Income70.63M67.15M96.57M132.40M263.26M359.72M371.83M119.72M191.58M113.19M
Operating Margin19.02%15.57%20.01%23.94%31.73%30.12%25.32%12.28%17.18%9.97%
EBITDA83.28M78.98M112.23M149.02M281.51M382.52M411.36M204.89M274.26M168.75M
EBITDA Margin22.43%18.31%23.26%26.95%33.93%32.03%28.01%21.01%24.59%14.86%
Net Income60.52M54.49M85.67M113.59M225.88M310.99M326.04M109.13M171.63M51.51M
Net Income Margin16.30%12.63%17.75%20.54%27.23%26.04%22.20%11.19%15.39%4.54%
R&D14.83M16.79M18.86M22.33M36.98M58.29M72.35M47.81M53.04M45.60M
R&D as % of Total Revenue3.99%3.89%3.91%4.04%4.46%4.88%4.93%4.90%4.76%4.02%
Interest Expense1.01M1.54M455.95K858.79K187.98K265.81K274.50K1.68M3.20M5.65M
Interest Expense % of Total Revenue0.27%0.36%0.09%0.16%0.02%0.02%0.02%0.17%0.29%0.50%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets351.98M328.69M464.35M536.04M1.38B1.69B1.87B1.88B1.95B2.12B
Total Liabilities163.91M76.17M122.92M130.79M167.74M301.88M275.30M239.15M233.79M412.53M
Total Equity188.07M252.52M341.42M405.25M1.21B1.39B1.59B1.64B1.71B1.69B
Cash65.16M87.56M186.47M115.32M773.38M718.42M753.23M447.68M303.19M532.65M
Total Debt55.00M10.00M40.00M--935.42K313.56K31.46M38.91M-
Net Debt-10.16M-77.56M-146.47M-115.32M-773.38M-717.49M-752.92M-412.19M-264.28M-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow86.12M85.54M102.42M122.33M242.18M372.99M282.75M185.39M210.38M253.96M
Investing Cash Flow-66.97M52.99M-35.65M-100.66M-148.96M-316.69M-163.10M-397.43M-195.53M-
Financing Cash Flow11.03M-111.43M29.74M-92.94M577.20M-113.47M-155.13M-95.80M-118.23M-
Capital Expenditure11.03M12.52M35.87M102.30M108.57M275.56M172.18M121.82M109.61M111.60M
Free Cash Flow75.09M73.03M66.56M20.04M133.61M97.43M110.57M63.57M100.77M142.35M
Dividends Paid23.97M66.43M255.39K50.69M-144.00M155.43M90.10M81.23M65.68M
FCF to OCF87.20%85.37%64.98%16.38%55.17%26.12%39.10%34.29%47.90%56.05%
Dividend Paid to FCF31.92%90.97%0.38%252.96%-147.80%140.57%141.73%80.60%46.14%

Earnings

Report DateSep 30, 2020Mar 9, 2021Apr 20, 2021Aug 24, 2021Oct 21, 2021Dec 31, 2021Apr 17, 2022Aug 22, 2022Oct 27, 2022Dec 31, 2022Apr 24, 2023
EPS Estimate-----------
EPS Actual0.620.600.990.871.070.530.841.030.880.160.26
Surprise-----------
Timing--Pre-marketAfter-hoursPre-market-Pre-marketPre-marketPre-market-Pre-market

Key Statistics & Ratios

Market Cap4.00B
Enterprise Value3.48B
Trailing P/E72.80
Forward P/E0.00
Price / Sales3.43
Price / Book2.32
EPS0.25
Book Value7.72
Revenue (TTM)1.17B
Gross Profit (TTM)309.38M
EBITDA193.19M
Profit Margin4.79%
Operating Margin9.42%
Return on Equity3.24%
Return on Assets3.12%
Shares Outstanding219.80M
Shares Float65.97M
Beta0.59
Dividend Yield0.82%
Dividend Rate0.15
Payout Ratio60.00%

Dividends

20261×
0.15Jun 18, 2026
20251×
0.29Jun 26, 2025
20242×
0.21Oct 22, 20240.21Jul 9, 2024
20232×
0.26Oct 13, 20230.15Jun 2, 2023
20221×
0.70Jun 2, 2022
20211×
0.66Apr 15, 2021

Stock Splits

  • Jun 26, 20251.4:1
  • Jul 9, 20241.4:1
  • Apr 15, 20211.4:1